Located in Redmond WA, founded in 2014, SystImmune Inc. is a biopharmaceutical company focused on the treatment of cancer through developing novel therapeutic bi-specific, and multi-specific antibodies, as well as antibody-drug conjugates (ADC's). Our objective is to create biologics that work through systematic intervention on solid tumor microenvironment, to either directly attack the tumor and/or to activate the immune system to attack the tumor. We are a group of highly experienced immuno-oncology scientists utilizing several technology platforms to develop world class advanced antibody-based drug therapies.
SystImmune Inc., is a wholly owned and subsidiary of a pharmaceutical company and funded by venture capital firm OrbiMed. We are willing to seek parties interested in working with as partners to develop, commercialize, and bring our novel therapeutics to patients around the world.
SystImmune Inc., has established three major technology platforms for the discovery and development of novel bio-therapeutics:
- Antibody discovery: identification of monoclonal antibodies with unique characteristics through screening of thousands of target-specific IgG producing B cells using novel miniaturized immuno-assays
- Multi-specific antibody engineering platforms
- Process development platforms to manufacture our bio-therapeutics